Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCTerminated
NCT05733611Phase 2Updated Feb 2, 2026
Sponsor: Replimune, Inc.
Refractory Metastatic Colorectal Cancer · pMMR · MSS
United States
National Register of Actionable MutationsActive Not Recruiting
NCT05918666N/AUpdated Jan 30, 2026
Sponsor: Federation of Italian Cooperative Oncology Groups
Solid Tumours in Advanced Stages
Italy
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompleted
NCT04294810Phase 3Updated Jan 30, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Australia, Austria, Brazil, China +18 more
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsRecruiting
NCT05300282Phase 1, Phase 2Updated Jan 28, 2026
Sponsor: Fondazione Italiana Linfomi - ETS
Relapsed or Refractory Hodgkin's Lymphoma
Italy
Development of an Innovative Clinico-biological Score for the Early Detection of Acute Renal Failure Associated With Cardiac Surgery.Completed
NCT05283213N/AUpdated Jan 26, 2026
Sponsor: Nantes University Hospital
Acute Kidney Injury
France
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompleted
NCT04158648Phase 3Updated Jan 23, 2026
Sponsor: Hoffmann-La Roche
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor · Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor · Hemophilia A
United States, Belgium, Canada, France, Germany +5 more
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)Completed
NCT03456063Phase 3Updated Jan 22, 2026
Sponsor: Hoffmann-La Roche
Non-Small-Cell Lung
United States, Australia, Austria, Brazil, China +19 more
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus InfectionTerminated
NCT05763576Phase 1Updated Jan 22, 2026
Sponsor: Hoffmann-La Roche
Chronic Hepatitis B
United States, Hong Kong, New Zealand, South Korea, Spain +2 more
Avo In R/R And Previously Untreated MCLRecruiting
NCT04855695Phase 1, Phase 2Updated Jan 21, 2026
Sponsor: Austin I Kim
Mantle Cell Lymphoma · Refractory Lymphoma
United States
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabCompleted
NCT04998851Phase 4Updated Jan 14, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis · Clinically Isolated Syndrome
United States, Spain, United Kingdom
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility StudyRecruiting
NCT07334379Phase 2Updated Jan 12, 2026
Sponsor: Lorenzo delSorbo
Acute Hypoxemic Respiratory Failure
Canada
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyTerminated
NCT04770272Phase 2Updated Jan 12, 2026
Sponsor: Palleos Healthcare GmbH
Triple-negative Breast Cancer
Germany
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyTerminated
NCT04578106Phase 2Updated Jan 6, 2026
Sponsor: Fundacio Clinic Barcelona
HER2-positive Breast Cancer · Stage I Breast Cancer
Spain
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot StudyRecruiting
NCT07163611Phase 2, Phase 3Updated Jan 6, 2026
Sponsor: Radboud University Medical Center
Membranous Nephropathy - PLA2R Induced
Netherlands
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active Not Recruiting
NCT05904886Phase 3Updated Dec 31, 2025
Sponsor: Hoffmann-La Roche
Hepatocellular Carcinoma
United States, Belgium, Brazil, Canada, China +22 more
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical PracticeRecruiting
NCT06008691N/AUpdated Dec 29, 2025
Sponsor: Fondazione Italiana Linfomi - ETS
Non-Hodgkin Lymphoma, B-cell
Italy
Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)Recruiting
NCT06695325N/AUpdated Dec 26, 2025
Sponsor: Tameside General Hospital
Diabetes Mellitus
United Kingdom
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerCompleted
NCT04148911Phase 3Updated Dec 26, 2025
Sponsor: Hoffmann-La Roche
Triple-Negative Breast Cancer
Argentina, Chile, Czechia, France, Hungary +8 more
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive Not Recruiting
NCT00781612Phase 2Updated Dec 24, 2025
Sponsor: Genentech, Inc.
Neoplasm Metastasis
United States, Australia, Belgium, Brazil, Bulgaria +30 more
Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical ResearchCompleted
NCT06343220N/AUpdated Dec 23, 2025
Sponsor: Huntington Study Group
Huntington Disease
United States
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive Not Recruiting
NCT04075266Phase 2Updated Dec 23, 2025
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
United States, Italy, Poland
Study of Two Dosages of Roaccutane in Cystic AcneCompleted
NCT07228481Phase 4Updated Dec 23, 2025
Sponsor: Premier Specialists, Australia
Acne Cystic
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompleted
NCT04471428Phase 3Updated Dec 22, 2025
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, France +10 more
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompleted
NCT04182204Phase 3Updated Dec 22, 2025
Sponsor: Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
United States, Brazil, Canada, China, Finland +11 more
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive Not Recruiting
NCT04446117Phase 3Updated Dec 18, 2025
Sponsor: Exelixis
Metastatic Prostate Cancer · Prostate Adenocarcinoma
United States, Argentina, Australia, Austria, Belgium +22 more

Previous page Next page